Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial

Faced with the novelty of a 212Pb-labeled monoclonal antibody (mAb) for clinical translation, concerns were expressed by the Food and Drug Administration (FDA) regarding 212Pb prematurely released from the mAb-chelate conjugate. The objective of this study was to simulate the worst case scenario of...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Diane E. Milenic, Alfredo A. Molinolo, María S. Solivella, Eileen Banaga, Julien Torgue, Sarah Besnainou, Martin W. Brechbiel, Kwamena E. Baidoo
Format:	Article
Language:	English
Published:	MDPI AG 2015-07-01
Subjects:	Pb-212 FDA toxicity study radioimmunotherapy targeted alpha-radiation
Online Access:	http://www.mdpi.com/1424-8247/8/3/416